Qalitex Warns of Growing FDA-Amazon Enforcement Overlap

Compliance and product testing firm Qalitex Laboratories has issued a warning to dietary supplement and wellness product sellers on Amazon, highlighting a growing overlap between FDA’s enforcement and Amazon’s compliance policies. The industry advisory outlines how Amazon has increasingly aligned its internal compliance standards with FDA regulations — a shift that is raising the stakes for brands selling on the e-commerce giant’s platform.

 Historically, FDA oversight and Amazon’s marketplace enforcement operated independently, the group’s advisory says. But recent patterns show that FDA Warning Letters, import alerts, and recall announcements are now triggering direct enforcement actions from Amazon. “Sellers whose products are cited in FDA warnings may see their listings suspended or removed before they’ve had a chance to respond to the agency,” the advisory warns. Amazon reportedly tracks FDA databases and acts quickly when compliance issues are flagged.

The aligned enforcement approach is presumably in response to a number of FDA Warning Letters over the past few years that called out the retailer’s lack of oversight. For example, in April the agency sent a Warning Letter saying it purchased from Amazon external analgesic products intended to be used before sensitive cosmetic procedures. The Warning Letter said the products are also unapproved new drugs that are misbranded. “FDA has safety concerns about external analgesic drug products formulated with active ingredients at concentrations that exceed levels currently permitted for nonprescription external analgesic products because they are intended to be used before or during certain cosmetic procedures in ways that could lead to increased absorption of the drug product through the skin,” the letter said.

According to Qalitex, common violations that are drawing joint attention from FDA and Amazon include:

• Unsubstantiated health or disease treatment claims
• Misbranded or undeclared ingredients
• Inadequate labeling that fails to meet FDA standards
• Shelf-life claims without supporting stability data
• Manufacturing lapses related to Good Manufacturing Practices (GMP)

Amazon’s compliance systems reportedly use public FDA data to identify at-risk products — even if the specific seller hasn’t been named in an official enforcement action.

To help companies prepare, Qalitex is urging sellers to treat FDA and Amazon compliance as interconnected. It advises brands to maintain audit-ready documentation and monitor FDA databases regularly. It also recommends internal audits of Amazon listings and periodic reviews by regulatory experts. “Amazon compliance can no longer be treated separately from FDA oversight,” says Qalitex. “The new reality demands complete, defensible documentation and a proactive approach to risk management.”